



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Young et al.

Docket No.: PF513P1

Application No.: 10/068,956

Confirmation No.: 2381

Filed: February 11, 2002

Art Unit: 1653

For: PGRP-L Polynucleotides, Polypeptides, and  
Antibodies

Examiner: K. C. Carlson

**INFORMATION DISCLOSURE STATEMENT (IDS)**  
**PURSUANT TO 37 C.F.R. § 1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references A-J listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: April 1, 2004

Respectfully submitted,

By Joseph Schuller  
Joseph Schuller

Registration No.: 48,708  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(240) 314-4400 x2534

MJH/JS/KN/ba



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/068,956-Conf. #2381
Filing Date	February 11, 2002
First Named Inventor	Paul E. Young
Art Unit	1653
Examiner Name	K. C. Carlson
Attorney Docket Number	PF513P1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A	WO-00/05367-A2	02-03-2000	Sagami Chemical Research Center		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B	WANG et al., "Human Peptidoglycan Recognition Protein-L Is an N-Acetylmuramoyl-L-alanine Amidase," <i>J. Biol. Chem.</i> 278(49):49044-49052 (Dec. 5, 2003).	
	C	LIU et al., "Peptidoglycan Recognition Proteins," <i>J. Biol. Chem.</i> 276(37):34686-34694 (Sep. 14, 2001).	
	D	HILLIER et al., GenBank Accession No. AA121766, "zn95a11.r1 Stratagene fetal retina 937202 Homo sapiens cDNA clone IMAGE:565916 5' similar to contains L1.b1 L1 repetitive element, mRNA sequence". (Feb. 2, 1997)	
	E	NCI-CGAP, GenBank Accession No. AA829438, "od27d10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1369171 3' similar to contains L1.t3 L1 repetitive element, mRNA sequence". (Mar. 31, 1998).	
	F	DE PAUW et al., "Characterization of human serum N-acetylmuramyl-L-alanine amidase purified by affinity chromatography," <i>Protein Expr. Purif.</i> 6(3):371-378 (Jun. 1995).	
	G	OCHIAI et al., "A Pattern Recognition Protein for Peptidoglycan," <i>J. Biol. Chem.</i> 274(17):11854-11858 (Apr. 23, 1999).	
	H	KANG et al., A peptidoglycan recognition protein in innate immunity conserved from insects to humans," <i>Proc. Natl. Acad. Sci. USA</i> 95:10078-10082 (Aug. 1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/068,956-Conf. #2381
				Filing Date	February 11, 2002
				First Named Inventor	Paul E. Young
				Art Unit	1653
				Examiner Name	K. C. Carlson
				Attorney Docket Number	PF513P1
Sheet	2	of	2		

I	REHMAN et al., "Cloning and expression of peptidoglycan recognition protein (PGRP) in the brain and spleen of rattus norvegicus," <i>Society for Neuroscience Abstracts</i> , 25(1-2):1445 (1999), abstract no. 580.4.	
J	International Search Report for International Application No. PCT/US00/22877 dated Feb. 7, 2001.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--